The FDA has approved Novavax’s protein-based COVID-19 vaccine, giving some Americans another option besides messenger RNA vaccines to prevent SARS-CoV-2 infection.

The U.S. Food and Drug Administration (FDA) has granted full approval to Novavax's COVID-19 vaccine, but only for certain ...

U.S. stocks were mostly lower in choppy trading on Monday with market sentiment weakened by the downgrade of the federal ...

RFK Jr. pledged not to upend US vaccine system, but big changes are underway. It's unclear which shots will be available.

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

Tesla's Chinese rival Xiaomi announced its electric SUV set to compete with Tesla's Model Y will be launched Thursday. TXNM ...

Novavax had expected full approval for broader use by April 1, after the FDA reviewed data from a 30,000-person clinical ...

In the options pits, NVAX has already seen quadruple the overall options volume it typically sees in an entire session, with ...

Novavax Inc. jumped after US regulators fully approved its Covid vaccine, easing investors’ concerns after the clearance was ...

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at the opening bell Monday.